A Simple Platform for the Rapid Development of Antimicrobials

Area of Science:

• Microbiology
• Drug Discovery
• Biotechnology

Background:

• Recent infectious outbreaks necessitate rapid development of novel therapeutics.
• Existing antimicrobial development pipelines are often too slow for emerging pathogens.

Purpose of the Study:

• To present a feasible platform technology for the rapid, one-week development of antimicrobial interventions.
• To demonstrate the production of thousands of doses of a new antimicrobial agent.

Main Methods:

• Development of a system utilizing antimicrobial synbodies, which are pairs of peptides.
• Pre-screening of 100 peptides for broad antimicrobial activity and low cell toxicity.
• Assaying pathogens on a chip to identify effective peptides, followed by synbody formation and screening.

Main Results:

• Demonstrated the feasibility of a one-week antimicrobial development process.
• Identified peptide combinations (synbodies) with potential antimicrobial activity and low toxicity.
• Established a pathway for rapid, large-scale production of lead synbody candidates.

Conclusions:

• The peptide synbody platform offers a rapid and scalable solution for developing new antimicrobials against emerging infectious diseases.
• This technology can significantly shorten the response time to novel pathogen threats.
• Further development and validation of this platform are warranted for public health preparedness.